MARKET

RAPP

RAPP

Rapport Therapeutics Inc
NASDAQ
30.76
+1.16
+3.92%
After Hours: 30.76 0 0.00% 16:11 12/16 EST
OPEN
29.37
PREV CLOSE
29.60
HIGH
31.02
LOW
28.53
VOLUME
268.12K
TURNOVER
--
52 WEEK HIGH
42.27
52 WEEK LOW
6.43
MARKET CAP
1.47B
P/E (TTM)
-11.3326
1D
5D
1M
3M
1Y
5Y
1D
Rapport Therapeutics Chief Scientific Officer David Bredt Reports Sale of Common Shares
Reuters · 6h ago
Weekly Report: what happened at RAPP last week (1208-1212)?
Weekly Report · 1d ago
Rapport Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/09 18:33
Rapport Therapeutics Price Target Raised to $40.00/Share From $34.00 by HC Wainwright & Co.
Dow Jones · 12/09 18:33
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $40
Benzinga · 12/09 18:23
Rapport Therapeutics price target raised to $40 from $34 at H.C. Wainwright
TipRanks · 12/09 11:10
Promising Outlook for Rapport Therapeutics: Buy Rating Backed by RAP-219’s Clinical Success and Strategic Growth Plans
TipRanks · 12/08 17:45
Rapport Therapeutics Price Target Maintained With a $47.00/Share by BTIG
Dow Jones · 12/08 10:56
More
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

Webull offers Rapport Therapeutics Inc stock information, including NASDAQ: RAPP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RAPP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RAPP stock methods without spending real money on the virtual paper trading platform.